Senescent cells: the therapeutic target against pulmonary aging

The accumulation of senescent cells in lung tissue emerges as the central mechanism explaining why chronic pulmonary diseases—idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease—accelerate with age and metabolic stress from obesity or type 2 diabetes. These dormant cells, initially protective against uncontrolled proliferation, secrete inflammatory and profibrotic mediators that perpetuate a destructive cycle: chronic inflammation, endothelial dysfunction, fibrotic remodeling, and collapsed regenerative capacity. An early academic clinical trial using senolytics—drugs designed to eliminate these cells—produced promising results in patients with idiopathic pulmonary fibrosis, though clinical follow-up has remained sparse due to lack of financial incentives for funding expensive late-stage trials. What matters for the longevity-focused reader: these diseases are not inevitable with age, but manifestations of accelerated aging that respond to a single biological denominator. Targeting senescent cells offers the unique opportunity to intervene on the root causes of aging itself, not merely its symptoms.